3.3. Pre-Treatment of Cancer Ex Vivo with Lenvatinib Contribute to Reduction of PD-L1 Expression and to Reduced Proliferation Levels While Using T Cells and Pembrolizumab. This evidence concerns the gene CD274 and cancer.